IMAGE

Figure 5

ID: ZDB-IMAGE-200410-12
Publication: He et al., 2020 - Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
All Figures: Figures for He et al., 2020

Image

Figure Caption

Figure 5 <italic><styled-content toggle='no' style='fixed-case'>FST</styled-content></italic> knockdown reduced <styled-content toggle='no' style='fixed-case'>AML</styled-content> cell growth <italic>in vitro</italic> and <italic>in vivo</italic>

FST knockdown in MOLM‐13 by shRNA effectively reduced FST expression.

B–E

The morphology (B), apoptosis (C), and clonogenicity of MOLM‐13 (D and E) were measured after FST knockdown in vitro. Scale bar = 10 μm. The apoptosis assays (C) were performed in triplicates.

F, G

The engraftment of MOLM‐13 after FST knockdown was detected by flow cytometry of human CD45‐ and mouse CD45.1‐positive cells in recipient mouse BM aspiration at week 2 post‐transplantation.

The effect of FST knockdown on the survival of NSG mice engrafted with MOLM‐13. scr: scrambled sequence control (7 mice); sh: short hairpin RNA (8 mice for sh1 and sh2, respectively). The survival curve was analyzed by log‐rank test. **P < 0.01.

Data information: In (C, E, and G), data were presented as mean ± SEM. *P < 0.05 and **P < 0.01 (Student's t‐test).Source data are available online for this figure.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ EMBO Mol. Med.